320 related articles for article (PubMed ID: 26943456)
21. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Sviggum HP; Davis MD; Rajkumar SV; Dispenzieri A
Arch Dermatol; 2006 Oct; 142(10):1298-302. PubMed ID: 17043184
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
[TBL] [Abstract][Full Text] [Related]
23. Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience.
Nakaya A; Fujita S; Satake A; Nakanishi T; Azuma Y; Tsubokura Y; Hotta M; Yoshimura H; Ishii K; Ito T; Nomura S
Acta Haematol; 2017; 138(1):55-60. PubMed ID: 28728162
[TBL] [Abstract][Full Text] [Related]
24. Pomalidomide for the management of refractory multiple myeloma.
Summers BB; Cole SW; Olin JL
Am J Health Syst Pharm; 2014 Sep; 71(17):1443-8. PubMed ID: 25147167
[TBL] [Abstract][Full Text] [Related]
25. [IMiDs in hematology].
Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
[TBL] [Abstract][Full Text] [Related]
26. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
27. [Immunomodulator drugs for the treatment of multiple myeloma].
Fernández-Lázaro D; Fernández-Lázaro CI; Caballero García A; Córdova Martínez A
Rev Med Chil; 2018 Dec; 146(12):1444-1451. PubMed ID: 30848748
[TBL] [Abstract][Full Text] [Related]
28. Severe hypocalcemia due to lenalidomide.
Kong S; Collet P; Marotte H; Thomas T
Joint Bone Spine; 2015 Oct; 82(5):380-1. PubMed ID: 25726251
[No Abstract] [Full Text] [Related]
29. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
30. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
[No Abstract] [Full Text] [Related]
31. Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
Srkalovic G; Hussein M
Bosn J Basic Med Sci; 2009 Oct; 9 Suppl 1(Suppl 1):S3-S10. PubMed ID: 19912117
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
33. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
34. Thrombosis in multiple myeloma (MM).
Cesarman-Maus G; Braggio E; Fonseca R
Hematology; 2012 Apr; 17 Suppl 1(0 1):S177-80. PubMed ID: 22507814
[TBL] [Abstract][Full Text] [Related]
35. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis.
Ying L; YinHui T; Yunliang Z; Sun H
Oncotarget; 2017 Jul; 8(28):46593-46600. PubMed ID: 28423741
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
38. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
40. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
Shortt J; Hsu AK; Johnstone RW
Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
